Phase 2 Start

MIRM: Phase2_Start: MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP) (OASIS)

Name: Phase2_Start: MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP) (OASIS)
Start: 2027-01-15
End: 2027-01-15

January 15, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 15, 2027
Company: Mirum Pharmaceuticals, Inc. (MIRM)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 2 Start

Phase2_Start: MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP) (OASIS)

January 15, 2027

MIRM overview →

Company: Mirum Pharmaceuticals, Inc. (MIRM)